The estimated Net Worth of Stephen M Kanovsky is at least $750 Thousand dollars as of 10 August 2024. Mr. Kanovsky owns over 11,336 units of Neogenomics stock worth over $588,628 and over the last 5 years he sold NEO stock worth over $0. In addition, he makes $161,868 as Independent Director at Neogenomics.
Stephen has made over 1 trades of the Neogenomics stock since 2024, according to the Form 4 filled with the SEC. Most recently he exercised 11,336 units of NEO stock worth $184,890 on 10 August 2024.
The largest trade he's ever made was exercising 11,336 units of Neogenomics stock on 10 August 2024 worth over $184,890. On average, Stephen trades about 1,619 units every 0 days since 2019. As of 10 August 2024 he still owns at least 36,090 units of Neogenomics stock.
You can see the complete history of Mr. Kanovsky stock trades at the bottom of the page.
Stephen Michael Kanovsky serves as Independent Director of the Company. Mr. Kanovsky, who has worked at General Electric since 2012, is General Counsel, Commercial of GE Healthcare, a business unit of General Electric that provides medical technologies and solutions to the global healthcare industry and supports customers in over 100 countries with a broad range of services and systems, from diagnostic imaging and healthcare IT through to molecular diagnostics and life sciences. Mr. Kanovsky earned his bachelor’s degree from the University of Pennsylvania. He subsequently graduated from Temple University’s School of Pharmacy with a master’s degree in Pharmacology and Temple University’s School of Law with a juris doctorate degree. Mr. Kanovsky also holds a master’s degree in business administration from Saint Joseph’s University’s Haub School of Business.
As the Independent Director of Neogenomics, the total compensation of Stephen Kanovsky at Neogenomics is $161,868. There are 14 executives at Neogenomics getting paid more, with Douglas VanOort having the highest compensation of $3,648,730.
Stephen Kanovsky is 57, he's been the Independent Director of Neogenomics since 2017. There are 12 older and 13 younger executives at Neogenomics. The oldest executive at Neogenomics Inc. is Raymond Hipp, 77, who is the Independent Director.
Stephen's mailing address filed with the SEC is 9490 NEOGENOMICS WAY, , FORT MYERS, FL, 33912.
Over the last 12 years, insiders at Neogenomics have traded over $310,374,253 worth of Neogenomics stock and bought 167,456 units worth $1,699,153 . The most active insiders traders include Electric Coge Medical Syste..., Oort Douglas M Van, and Steven C Jones. On average, Neogenomics executives and independent directors trade stock every 23 days with the average trade being worth of $2,654,175. The most recent stock trade was executed by Alicia C Olivo on 15 August 2024, trading 1,040 units of NEO stock currently worth $16,692.
neogenomics laboratories is a leading cancer diagnostic reference laboratory that has provided high-quality cancer testing and partnership programs to pathologists and oncologists for over 10 years. we work every day to achieve our common purpose of saving lives by improving patient care through communication, accuracy, reliability, and efficiency. our areas of expertise include cancer cytogenetics with industry-leading turnaround times; hematologic and solid tumor fish testing with the largest menu of technical-only services available; 10-color flow cytometry; ihc supported by an extensive antibody library; and over 100 molecular oncology tests comprising the most comprehensive combination of multiparameter profiles and targeted biomarker tests in the industry. our technical-only testing programs feature on-demand or live training and are available to pathologists who wish to sign out fish, flow cytometry, and/or ihc. neogenomics’ extremely fast test development cycle means we are hig
Neogenomics executives and other stock owners filed with the SEC include: